Wechselwirkungen · Efavirenz Teva
Efavirenz Teva 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 18
HOS-215319 · Präparat HOS-155418
Efavirenz: no clinically significant interaction. The clinical significance of these effects is not known. Injection: In a 3-month drug interaction study, Because of the limited Depomedroxyprogesterone no significant differences in MPA information available, a reliable acetate (DMPA)/efavirenz pharmacokinetic parameters were method of barrier contraception (150 mg IM single dose DMPA) found between subjects receiving must be used in addition to efavirenz-containing antiretroviral hormonal contraceptives (see therapy and subjects receiving no section 4.6). antiretroviral therapy. Similar results were found by other investigators, although the MPA plasma levels were more variable in the second study. In both studies, plasma progesterone levels for subjects receiving efavirenz and DMPA remained low consistent with suppression of ovulation. Implant: Etonogestrel/efavirenz Decreased exposure of etonogestrel A reliable method of barrier may be expected (CYP3A4 contraception must be used in induction). There have been addition to hormonal occasional postmarketing reports of contraceptives (see section 4.6). contraceptive failure with etonogestrel in efavirenz-exposed patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): progesterone (HOS-090753) acetate (HOS-088133) etonogestrel (HOS-144596)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-03-03T18:18:00Z · SHA-256 d2c4a637bb18ba1e0c98c69218ce14671957659a5aa55fba40e74b1bf5620382 · Passage 8952614af172de542468d8f04a229b11865e1da72dd9cff88f789d1c400a8a34 · Zeichen 55262–57260 im Abschnitt